Seelos Therapeutics, Inc.
SEELQ
$0.0005
$0.000.00%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 11.90% | -28.34% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.90% | -28.34% | -- | -- | -- |
| Cost of Revenue | -90.84% | -37.81% | -48.62% | -- | -55.10% |
| Gross Profit | 95.21% | 39.38% | 49.74% | -- | 56.94% |
| SG&A Expenses | -8.31% | -23.65% | -0.22% | 12.29% | -3.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -68.86% | -31.89% | -52.54% | -25.28% | -46.85% |
| Operating Income | 71.34% | 32.21% | 56.12% | 27.61% | 48.43% |
| Income Before Tax | 105.80% | 80.17% | 70.77% | 153.55% | -38.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 105.80% | 80.17% | 70.77% | 153.55% | -38.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 105.80% | 80.17% | 70.77% | 153.55% | -38.66% |
| EBIT | 71.34% | 32.21% | 56.12% | 27.61% | 48.43% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 101.27% | 94.28% | 84.94% | 142.22% | -11.48% |
| Normalized Basic EPS | 100.29% | 97.93% | 86.48% | 167.38% | 11.26% |
| EPS Diluted | 100.23% | 94.28% | 84.94% | 37.04% | -11.49% |
| Normalized Diluted EPS | 100.29% | 97.93% | 86.48% | 161.55% | 11.26% |
| Average Basic Shares Outstanding | 355.52% | 246.75% | 94.07% | 26.86% | 24.64% |
| Average Diluted Shares Outstanding | 356.98% | 246.75% | 94.07% | 38.85% | 24.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |